Phrontline Biopharma
Phrontline Biopharma develops innovative antibody-drug conjugates (ADCs) focused on oncology therapies.
Amount raised
$40M
Round
Series A
Date raised
November 13, 2026
Founded
2022
CompanyPhrontline Biopharma
IndustryBiotechnology
LocationHangzhou, China
InvestorsDecheng Capital, Oriza Seed Venture Capital
Websitewww.phrontlinebio.com
Founder
Get new raises like this every week
Free weekly list of newly funded startups and their founders.
About Phrontline Biopharma
Phrontline Biopharma develops innovative antibody-drug conjugates (ADCs) focused on oncology therapies.
- How much did Phrontline Biopharma raise?
- Phrontline Biopharma raised $40M in a Series A round on November 13, 2026. Investors include Decheng Capital, Oriza Seed Venture Capital.
- Who founded Phrontline Biopharma?
- Tony Chen founded Phrontline Biopharma in 2022.
- Where is Phrontline Biopharma based?
- Phrontline Biopharma is based in Hangzhou, China.